Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Cardio Diagnostics Holdings Inc. (symbol: CDIO) is a pioneering biotechnology company focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. Leveraging cutting-edge artificial intelligence, the company has developed a proprietary Genetic-Epigenetic Engine™ designed to revolutionize the management of cardiovascular health.
The main goal of Cardio Diagnostics is to enhance the accuracy and efficacy of cardiovascular disease prevention and treatment. The company's flagship technology integrates genetic and epigenetic data to provide a comprehensive understanding of an individual’s cardiovascular risk, enabling targeted interventions and personalized care plans. This innovative approach aims to reduce the incidence of cardiovascular events and improve patient outcomes.
Recent achievements include expanding their product portfolio and forming strategic partnerships with leading healthcare providers to broaden the reach of their diagnostic tools. The company is also actively involved in research projects aimed at further enhancing their AI-driven platform's capabilities. Financially, Cardio Diagnostics Holdings Inc. has seen steady growth, marked by increasing investor interest and promising market forecasts.
With a dedicated team of experts in genetics, bioinformatics, and clinical research, Cardio Diagnostics continues to push the boundaries of medical technology. Their commitment to advancing cardiovascular healthcare promises significant strides in the early detection and prevention of one of the leading causes of mortality worldwide.
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) partners with Navierre to expand access to AI-enabled precision cardiovascular diagnostic tests, aiming to revolutionize cardiovascular care. The collaboration leverages telehealth to provide early detection, personalized prevention, and management of heart disease, addressing the critical need for innovative clinical solutions. Cardio Diagnostics' suite of AI-driven tests, Epi+Gen CHD and PrecisionCHD, offer actionable insights for improved patient outcomes. Starting April 1, 2024, these tests will be available through Navierre's platform, catering to a broader audience and breaking down barriers to specialty cardiovascular care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (CDIO) to showcase HeartRiskTM and Actionable Clinical IntelligenceTM platforms at ACC.24. The company focuses on precision cardiovascular medicine using AI and advanced technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) secures a new U.S. patent for detecting predisposition to cardiovascular disease, expanding its global IP portfolio. The company's founders, Dr. Meesha Dogan and Dr. Robert Philibert, receive co-inventorship. The patented technology aims to combat the rising burden of heart disease in the U.S. with innovative solutions like Epi+Gen CHD and PrecisionCHD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.09%
Tags
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) announces the nationwide rollout and significant expansion of its HeartRisk™ platform, combining clinical data with industry insights for real-time population-level cardiovascular disease risk management. The platform now extends to correctional facilities, risk-bearing providers, and benefits organizations, addressing financial and security challenges. The company aims to empower healthcare stakeholders with data-driven decisions to tackle rising costs and enhance chronic disease management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) announced the introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a retail healthcare setting at the Round Lake Beach Walmart Supercenter in Illinois. The tests will be available beginning Q2 2024, marking a strategic expansion of the ongoing Heart Attack Prevention Initiative with Family Medicine Specialists (FMS). The initiative aims to increase accessibility of clinical cardiovascular diagnostic solutions, making them available to more patients beyond traditional provider settings. The partnership with FMS is expected to democratize access to top-tier heart disease services and position Cardio Diagnostics as a leader in cardiovascular retail healthcare innovation. The tests, Epi+Gen CHD and PrecisionCHD, detect heart attack risk and coronary heart disease status, respectively, and will be offered on a walk-in basis, making the vital service more accessible to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) announces a collaboration with resTOR Longevity Clinic to integrate its innovative blood-based epigenetic tests for cardiovascular disease into the clinic's testing regime for new patients. The partnership aims to push the boundaries of modern medicine to transform innovation in cardiovascular medicine with an emphasis on living a longer and healthier life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has appointed Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and health innovation leader with a strong academic and professional background. His appointment is expected to drive the company's growth and market expansion, leveraging his expertise in cardiovascular medicine, innovation, and research. Dr. Ramjee's role will accelerate the company's mission of improving patients' lives in the prevention, treatment, and management of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, a pioneering AI-driven precision cardiovascular medicine company, announced that India’s Patent Office has granted a patent to the University of Iowa Research Foundation under patent number 484488. The patent was exclusively licensed to the Company from the University of Iowa Research Foundation and co-invented by Cardio Diagnostics’ founders, Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D. The Company’s global patent portfolio includes granted patents in the United States, Europe, India, Australia, China, and Hong Kong, and numerous pending patents worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.13%
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, an AI-driven precision cardiovascular medicine company (Nasdaq: CDIO), introduces HeartRisk to help employers understand and mitigate cardiovascular risks in their workforce. HeartRisk provides actionable insights related to cardiovascular disease, such as the amount of stop-loss insurance to carry based on the degree of CVD risk in the relevant population or selections of appropriate chronic care management partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
Rhea-AI Summary
CARDIO DIAGNOSTICS HOLDINGS, INC. (Nasdaq: CDIO) introduces HeartRisk™, an employer cardiovascular disease risk intelligence platform to combat cardiovascular disease in the workforce and mitigate business risks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
FAQ
What is the current stock price of Cardio Diagnostics Holdings (CDIO)?
The current stock price of Cardio Diagnostics Holdings (CDIO) is $0.255 as of November 15, 2024.
What is the market cap of Cardio Diagnostics Holdings (CDIO)?
The market cap of Cardio Diagnostics Holdings (CDIO) is approximately 7.3M.
What does Cardio Diagnostics Holdings Inc. do?
Cardio Diagnostics Holdings Inc. specializes in cardiovascular disease prevention and early detection using a proprietary Genetic-Epigenetic Engine™ driven by artificial intelligence.
What is the Genetic-Epigenetic Engine™?
The Genetic-Epigenetic Engine™ integrates genetic and epigenetic data to provide a precise understanding of cardiovascular risk and facilitate personalized care.
What are the recent achievements of Cardio Diagnostics Holdings Inc.?
Recent achievements include expanding their product portfolio and forming strategic partnerships with leading healthcare providers.
How does Cardio Diagnostics' technology benefit patients?
Their technology allows for early detection and personalized prevention of cardiovascular disease, improving patient outcomes and reducing health risks.
Are there any ongoing research projects at Cardio Diagnostics?
Yes, the company is actively involved in research to further enhance the capabilities of their AI-driven platform.
What is the financial outlook for Cardio Diagnostics Holdings Inc.?
The company has seen steady financial growth with increasing investor interest and promising market forecasts.
What makes Cardio Diagnostics' approach unique?
Their integration of genetic and epigenetic data using artificial intelligence offers a highly precise and personalized approach to cardiovascular care.
Who are the key partners of Cardio Diagnostics?
Cardio Diagnostics has formed strategic partnerships with leading healthcare providers to expand the reach of their diagnostic tools.
What is the company's mission?
The company's mission is to make cardiovascular disease prevention and detection more accessible, personalized, and effective.
Where is Cardio Diagnostics Holdings Inc. based?
Further company details like location are available on their official website and financial reports.
Cardio Diagnostics Holdings Inc.
Nasdaq:CDIO
CDIO Rankings
CDIO Stock Data
7.34M
25.91M
13.03%
5.92%
3.35%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
United States of America
CHICAGO